Uzm. Dr. Muhammet Sedat OFLUOĞLU | Kolan Hospital

Uzm. Dr. Muhammet Sedat OFLUOĞLU

Nükleer Tıp ve Moleküler Görüntüleme
İstanbul Sağlık ve Teknoloji Üniversitesi Beylikdüzü Kolan Hospital muhammetsedat.ofluoglu@kolanhastanesi.com.tr Soru Sor

Uzm. Dr. Muhammet Sedat OFLUOĞLU

Nükleer Tıp ve Moleküler Görüntüleme
İstanbul Sağlık ve Teknoloji Üniversitesi Beylikdüzü Kolan Hospital
muhammetsedat.ofluoglu@kolanhastanesi.com.tr

Soru Sor
  1. Anasayfa
  2. Doktorlarımız
  3. Uzm. Dr. Muhammet Sedat OFLUOĞLU
Eğitim
  • 1992 Akdeniz Üniversitesi, Antalya Tıp Fakültesi
  • 2002 Viyana Üniversitesi
İlgi Alanları
  • Konvansiyonel Nükleer Tıp
  • PET-CT (Onkoloji)
  • Nükleer Tıp Tanı ve Tedavi Yöntemleri
  • Tiroid Hastalıkları Tanı ve Tedavi Yöntemleri
  • Tiroid Ultrasonu, Tiroid Gland ve Boyunda İİAB (Biyopsi)
Çalıştığı Kurumlar
  • 2002-2015 Alman Hastanesi , Kadıköy Vatan Hastanesi, ve İtalyan Hastanesi (Universal Hospitals Grup) Nükleer Tıp Bölümleri
  • 2015-2018 GOP- Taksim Eğitim Araştırma Hastanesi Nükleer Tıp Bölümü
  • 2018-2018 VM Medical Park Florya Üniversite Hastanesi
  • 2018-2022 LİV-Hospitali İSÜ Üniversite Hastanesi
  • 2023-Devam Beylikdüzü Kolan Hastanesi

Diğer

Üyelikler

  • Türk Tabipler Birliği
  • Türkiye Nükleer Tıp Derneği (TNTD)
  • Avrupa Nükleer Tıp Derneği (EANM)
  • Avusturya Nükleer Tıp Derneği (ÖGN)
  • Havacılık Tıbbı Derneği
  • HUTP Platformu
  • EASA

Eserler

Uluslararası hakemli dergilerde yayımlanan makaleler

  • Radiation exposure around patients after administration of 123I-Metaiodobenzylguanidine (MIBG). Sedat Ofluoglu, J. Preitfellner, T. Traub, C. Novotny, B. Füger, E. Havlik, A. Kurtaran. Nuklearmedizin 2002; 41: 221-3.
  • Radiation Synovectomy with Holmium-166 Ferric Hydroxide - a First Experience. Sedat Ofluoglu, E. Schwameis, H. Zehetgruber, E. Havlik, A. Wanivenhaus, I. Schweeger, K. Weiss, H. Sinzinger, C. Pirich. J Nucl Med. 2002 Nov;43(11):1489-94.
  • Strahlenexposition in der Umgebung von Patienten nach Gabe eines Radiopharmakons in der nulearmedizinischen Diagnostik. J. Preitfellner, A. Kurtaran, T. Traub, Sedat Ofluoglu, E. Havlik. Strahlenschutz 2000; 8: 13-19.
  • New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy. Virgolini I, Traub T, Leimer M, Novotny C, Pangerl T, Ofluoglu S, Halvadjieva E, Smith-Jones P, Flores J, Li SR, Angelberger P, Havlik E, Andreae F, Raderer M, Kurtaran A, Niederle B, Dudczak R. Q J Nucl Med. 2000 Mar;44(1):50-8. Review.
  • An unusual visualization of the gallbladder by somatostatin receptor (SSTR) scintigraphy: usefulness of hepatobiliary imaging for differential diagnosis. Kurtaran A, Ofluoglu S, Traub T, Tribl B, Speiser P, Grabenwöger F, Schima W, Dudczak R, Virgolini I. Am J Gastroenterol. 2000 May;95(5):1367-8.
  • 111In-DOTA-lanreotide scintigraphy in patients with tumors of the lung. T. Traub, V. Petkov, Sedat Ofluoglu, E. Havlik, P. Angelberger, F. Andraea, E. Halvadjieva, C. Brunner, W. Schima, A. Kurtaran, R. Dudczak, I. Virgolini. JNM 2001; 42: 1309-1315.
  • Impact of Localization Studies on Feasibility of Minimally Invasive Parathyroidectomy in an Endemic Goiter Region G, Prager, C. Czerny, Sedat Ofluoglu, A. Kurtaran, C. Passler, K. Kaczirek, C. Scheuba, B. Niederle. J Am Coll Surg 2003;196:541–548.
  • [Radiation doses deriving from patients treated with (166)Ho-ferric hydroxide]
    Preitfellner J, Pirich C, John P, Ofluoglu S, Sinzinger H, Havlik E. Nuklearmedizin. 2003 Dec;42(6):251-4. German.
  • Should lidocaine be avoided for local anesthesia in radiation synovectomy? Schweeger I, Pirich C, Ofluoglu S, Sinzinger H. Q J Nucl Med Mol Imaging. 2004 Sep;48(3):207-10.PMID: 15499294
  • Bone lesion detection with carrier-added 99mTc-EDTMP in comparison with 99mTc-DPD. Fueger BJ, Mitterhauser M, Wadsak W, Ofluoglu S, Traub T, Karanikas G, Dudczak R, Pirich C. Nucl Med Commun. 2004 Apr;25(4):361-5.
  • 13N-ammonia rest/stress PET: folic acid improves global coronary vasoreactivity in coronary artery disease patients with normal or elevated homocysteine levels. Graf S, Nikfardjam M, Khorsand A, Ofluoglu S, Nekolla S, Dudczak R, Maurer G, Kletter K, Huber K, Pirich C. Nuklearmedizin. 2006;45(6):248-53.PMID: 17149493
  • Incidence and predictability of amiodarone-induced thyrotoxicosis and hypothyroidism. Hofmann A, Nawara C, Ofluoglu S, Holzmannhofer J, Strohmer B, Pirich C.Wien Klin Wochenschr. 2008;120(15-16):493-8.
  • Coronary Vasoreactivity in Subjects with Thyroid Autoimmunity and Subclinical Hypothyroidism Before and After Supplementation with Thyroxine. Tatjana Traub-Weidinger, Senta Graf, Mohsen Beheshti, Sedat Ofluoglu, Georg Zettinig, Aliasghar Khorsand, Stephan G. Nekolla, Kurt Kletter, Robert Dudczak and Christian Pirich. The Thyroid 2012. VOL. 22 ( 3) :245-251.
  • Choroidal structural changes in airline pilots and cabin crew. Burcu Isık, Mehmet Giray Ersoz, Muhammet Sedat Ofluoglu.  International Ophthalmology 2023. Jun;43(6):1819-1823.

Uluslararası bilimsel toplantılarda sunulan ve bildiri kitabında (Proceedings) basılan bildiriler :

  • 111In-DOTA-lanreotide (111In-MAURITIUS) scintigraphy in patients with lung tumors. T. Traub, M. Leimer, A. Kurtaran, Sedat Ofluoglu, E. Havlik, P. Angelberger, M. Raderer, J. Flores, C. Brunner, P. Smith-Jones, R. Dudczak, I. Virgolini. J Nucl Med 1999; 40:98.
  • Human biodistribution, safety and absorbed dose of 99mTc-P1666 vasoactive intestinal peptide (VIP) receptor scintigraphy. I. Virgolini, T. Traub, Sedat Ofluoglu, A. Kurtaran, M. Raderer, S.R.Li, M. Beck, M. Leimer, P. Angelberger, E. Havlik, R. Dudczak, J. Lister-James. J Nucl Med 1999; 40:244.
  • 111In-DOTA-lanreotide (111In-MAURITIUS): a novel tracer for patients with lung tumours. T. Traub, V. Petkov, C. Brunner, A. Kurtaran, Sedat Ofluoglu, E. Havlik, M. Leimer, P. Angelberger, M. Raderer, R. Dudzcak, I. Virgolini. EJNM 1999; 29: 1036.
  • Comparative study of 111In-DOTA-lanreotide (LAN), 111In-DTPA-D-Phe-1-octreotide (OCT), 111In-DOTA-Tyr3-octreotide (TOCT) and F-18-PET in neuroendocrine tumor patients. I.Virgolini, A. Kurtaran, P. Smith-Jones, E. Havlik, T. Traub, M. Leimer, Sedat Ofluoglu, F. Andreae, M. Raderer, P. Angelberger, A. Becherer, B. Niederle, K. Kletter, W. Schima, R. Dudczak. EJNM 1999; 26: 1156.
  • 99mTC-P1666 vasoactive intestinal petide (VIP) receptor scintigraphy: clinical efficacy, biodistribution and safety. I.Virgolin, T. Traub, Sedat Ofluoglu, A. Kurtaran, M. Raderer, M. Beck, M. Leimer, P. Angelberger, S. Li, C. Novotny, E. Havlik, R. Dudczak, J. Lister-James. EJNM 1999; 26: 1154.
  • Comparative 111In-DOTA-lanreotide (LAN) and 111In-DOTA-Tyr3-octreotide (TOCT) scintigraphy: biodistribution and absorbed dose. E. Halvadjieva, P. Angelberger, F. Andreae, T. Traub, Sedat Ofluoglu, A. Kurtaran, E. Havlik, R. Dudczak, I. Virgolini. EJNM 1999; 26: 1119.
  • Experimental radiopeptide therapy (ERT) with 90Y-DOTA-Tyr3-DPHE1-octreotide. T. Traub, F. Andreae, P. Angelberger, Sedat Ofluoglu, M. Uffmann, A. Kurtaran, E. Halvadijeva, C. Novotny, R. Dudczak, I. Virgolini. J Nucl Med 2000; 41: 14.
  • Experimental 90Y-DOTA-Tyr3-DPHE1-octreotide therapy in patients with metastatic tumor disease. T. Traub, F. Andreae, P. Angelberger, M. Raderer, Sedat Ofluoglu, A. Kurtaran, E. Halvadjieva, R. Dudczak, I. Virgolini. EJNM 2000, A 7012.
  • Syndrom X-Mechanismen der reduzierten koronaren Flußreserve“ Graf S, Khorsand A, Gwechenberger M, Sedat Ofluoglu, Leitha Th, Kletter K, PirichCh, Schmaljohann J, Porenta G, Zehetgruber M Als Vortrag angenommen an der Jahrestagung der Österreichischen Gesellschaft für Nuklearmedizin, 4. Kongress, Februar 2001, Wien Nuklearmedizin 2001;40:A7.
  • Prädiktive Parameter für eine reduzierte koronare Flußreserve bei Patienten mit Angina Pektoris und blanden Koronarien“ Graf S, Khorsand A, Gwechenberger M, Sedat Ofluoglu, Leitha Th, Pirich Ch, Schmaljohann J, Sochor H, Porenta G, Zehetgruber M Als Vortrag angenommen an der Jahrestagung der Österreichischen Gesellschaft für Nuklearmedizin, 4. Kongress, Februar 2001, Wien Nuklearmedizin 2001;40:A8.
  • Myokardvitalität: NOGA Mapping im Vergleich mit FDG-PET und Tl-201 “Graf S, Glogar D, Khorsand A, Göngösy M, Pirich Ch, Sedat Ofluoglu, Leitha Th, Schmaljohann J, Sochor H, Porenta G Als Vortrag angenommen an der Jahrestagung der Österreichischen Gesellschaft für Nuklearmedizin, 4. Kongress, Februar 2001, Wien Nuklearmedizin 2001;40:A8.
  • Mechanisms of a reduced coronary flow reserve in patients with angina and normal angiogram“ Graf S, Khorsand A, Gwechenberger M, Sedat Ofluoglu, Pirich Ch, Kletter K, Dudczak R, Sochor H, Porenta G, Zehetgruber M Als Poster angenommen an der Society of Nuclear Medicine, 48th Annual Meeting, Juni 2001,Toronto.
  • Incidence and mechanisms of a reduced coronary flow reserve in patients with angina and normal angiogram“ Graf S, Khorsand A, Gwechenberger M, Sedat Ofluoglu, Krcal A, Pirich Ch, Kletter K, Sochor H, Porenta G, Zehetgruber M Als Vortrag angenommen am XXIII Annual Congress of the European Society of Cardiology, September 2001, Stockholm. Als Best-Abstract der am European Heart eingereichten österreichischen Abstracts Erhalt des „Byk-Reisestipendiums“ der Österreichischen Kardiologischen Gesellschaft.
  • Impaired coronary vasoreactivity in subjects with subclinical hypothyreoidism as evidenced by N-13-ammonia rest/stress PET. Pirich C, Sedat Ofluoglu, Graf S, Zettinig G, Traub T, Dobrocemsky G, Nekolla S, Dudczak R, Kletter K. J of Nucl Med. 2002, Vol 43, Iss 5, pp 183.
  • Impact of dietary supplementation with folic acid on coronary vasoreactivity in subjects with manifested coronary ertery disease as assessed by (13) NH (3) rest/stress PET. Pirich C, Nikfardjam M, Sedat Ofluoglu, Graf S, Nekolla S, Khorsand A, Dudczak R, Kletter K. J Nucl Med. 2002, Vol 43, Iss 5,pp 184.
  • Incidence and mechanisms of a reduced coronary flow reserve in patients with angina and normal angiogram. Zehetgruber M, Graf S, Khorsand A, Gwechenberger M, Sedat Ofluoglu, Pirich C, Porenta G, Sochor H, Krcal A, Kletter K. European Heart Journal 2001, Vol 22, pp 474-474.
  • Carbon-11 acetate PET imaging in prostate cancer patients with rising PSA after radical therapy. Prelimerly results. Kurtaran A, Wachter S, Becherer A, Sedat Ofluoglu, Schmaljohann J, Djavan B, Dudczak R, Kletter K. Eur. J. of Nucl. Med. 2001, Vol 28, Iss 8, pp OS 292.
  • The Vienna-protocol on repeated low-dose 153Sm-EDTMP therapy induces pain paliation and lesion regression/stabilisation. Sinzinger H, Weiss K, Granegger S, Sedat Ofluoglu, Kratzik CH, Hajek CH. Eur. J. of Nucl. Med. 2001, Vol 28, Iss 8, pp PS477.
  • Radiation hazard for patients and relatives after pain palliation with 30 mCi 153Sm-EDTMP Sinzinger H, Sedat Ofluoglu, Havlik E, Granegger S. Eur. J. of Nucl. Med. 2001, Vol 28, Iss 8, pp PS483.
  • Radiation synovectomy with Holmium-166 ferric hydroxide – A first experience. Sedat Ofluoglu, Schwameis E, Havlik E, Wanivenhaus a, Sinzinger H, Pirich C. Eur. J. of Nucl. Med. 2001, Vol 28, Iss 8, pp PS667.
  • Performing F-18-FDG and C-11-Methionine PET in the follow-up of gliomas after treatment – Are double investigations useful? Asenbaum S, Pirich C, Potzi C, Sedat Ofluoglu, Moameni A, Kletter K. Journal of Nucl. Med. 2001, Vol 42, Iss 5, pp 974.
  • Distinction between focal noduler hyperplasia (FHN) and liver metastasis by F-18- FDG PET. Kurtaran A, Becherer A, Mueller C, Raderer M, Schmaljohann J, Schima J, Sedat Ofluoglu, Dudczak R, Kletter K, Virgolini I. Journal of Nucl. Med. 2000, Vol 41, Iss 5, pp 1304.
  • Y-90-DOTA-Tyr3-DPHE1-Oktreotid Therapie bei Patienten mit metastasierter Tumorerkrankung. T. Traub, F. Andreae, P. Angelberger,M. Uffmann, P. M. Raderer, Sedat Ofluoglu, A. Kurtaran, , R. Dudczak, I. Virgolini. Nuklearmedizin 1/2001, V 14.
  • Bestimmung der Biodistribution und der Biokinetik von Radiopharmazeutika in der Therapie mit einem Ganzkörperzähler. H. Fischer, H. Aiginger, S. Granegger, E. Havlik, S. Ofluoglu, C. Pirich, H. Sinzinger, F. Steger . 2002, Leoben.
  • Tc-99m, Tc99m-MIBI, Tl-201-Chlorid, In-111-DTPA-D-Phe-1-Oct ve I-123 MIBG Aplikasyonu sonucu hastanın çevresine yaydığı radyasyon dozu. S. Ofluoğlu, J.Preitfellner, E.Havlik, L.Kabasakal ve A.Kurtaran. 5th international congress of nuclear oncology.1-5 mayis 2002, kusadasi.
  • Lenfödem kliniğimizde Takipli En Küçük Hasta: 21 AYLIK. Evrim Coşkun Çelik, Sedat Ofluoğlu, Gül Tuğba Bulut, GOP Taksim EAH, Fizik Tedavi ve Rehabilitasyon kliniği,  GOP Taksim EAH Nükleer Tıp Kliniği (2017, 2. Lenfödem Sempozyumu, Ankara)
Ulusal bilimsel toplantılarda sunulan ve bildiri kitaplarında basılan bildiriler

  • ‘Amiodarone ile oluşan tirotoksikoz ve hipotiroidizmin sıklığı ve önceden tahmin edilebilirliği’ Sedat Ofluoğlu, Andrea Hoffman, Johannes Holzmanhofer ve Christian Pirich. 3. Türkiye Tiroid Hastalıkları Kongresi. 18-20 Nisan 2008, Trabzon.
  • Tanısal amaçlı Nükleer Tıp uygulamalarında hastanın çevresine yaydığı radyasyon dozu. Sedat Ofluoglu, J. Preitfellner, B. J. Fueger, T. Traub, C.Novotny, E. Havlik ve A. Kurtaran. 5th international congress of nuclear oncology.1-5 mayis 2002, kusadasi.
  • Tc-99m, Tc99m-MIBI, Tl-201-Chlorid, In-111-DTPA-D-Phe-1-Oct ve I-123 MIBG Aplikasyonu sonucu hastanın çevresine yaydığı radyasyon dozu. S. Ofluoğlu, J.Preitfellner, E.Havlik, L.Kabasakal ve A.Kurtaran. 5th international congress of nuclear oncology.1-5 mayis 2002, kusadasi.

Diğer yayınlar: Toplantı Metinleri

  • A novel and promising tracer for patients with lung tumors: 111In-DOTA-lanreotide (111In-MAURITIUS). T. Traub, P. Petkov, C. Brunner, A. Kurtaran, Sedat Ofluoglu, E. Havlik, M. Leimer, P. Angelberger, M. Raderer, F. Andreae, R. Dudczak, I. Virgolini. 2nd International Wörthersee Symposium in Nuclear Medicine, Velden, Austria, May 13-15, 1999.
  • Clinical application of 111In-pentreotide, 111In-DOTA-lanreotide, and 123I-vasoactive intestinal peptide scintigraphy. T. Traub, Sedat Ofluoglu, M. Uffmann, A. Kurtaran, M. Raderer, J. Flores, R. Dudczak, I. Virgolini. International Symposium of Neuroendocrine Oncology, Biology and Clinical Aspects, Torino, Italy, March, 22nd-24th, 1999.